Head-to-head evidence
ALIA-1758 vs CM383
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Amyloid-beta (monoclonal antibody) · full Alzheimer's Disease pipeline
ALIA-1758
Developed by AbbVie
NCT06406348 · Phase 1 · completed
The trial was randomized and blinded against placebo, but it was conducted in healthy volunteers purely to check safety and dosing rather than cognitive or disease benefit, and no results have been posted yet.
CM383
Developed by Keymed Biosciences
NCT06412185 · Phase 1 · status unknown
This is a randomized, blinded, placebo-controlled study, but it is an early safety study in healthy volunteers rather than patients, and its primary measured outcome is safety rather than a disease outcome. Results have not yet been posted.
Next expected readout: December 2026 · NCT06619613 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALIA-1758's landscape · CM383's landscape